explore -WSS

explore

author：knowledge 2025-09-30 00:49:01 - browse：34686

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Bispecific antibodies are next new thing in cancer immunotherapy

WSS

The thinking behind the controversial eating disorder chatbot Tessa

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

HHS secretary Becerra pressed on Change HealthCare cyberattack

Millions may soon lose Medicaid when they don't have to

The thinking behind the controversial eating disorder chatbot Tessa

How to fix the rural physician shortage in the U.S.

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Novo pauses ads for weight loss drug Wegovy amid demand

Hepatitis C has a cure — but many Americans still lack access to it

A public health expert passes on football's full body collisions for youths

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA advisers back CAR

Peter Hotez and the public health issue of online harassment

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

New air purifier tech could be key to improving indoor air quality

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

explore

President Biden's budget: Here's what you might have missed

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

UCLA team creates talking throat patch for voice disorders

How to fix the rural physician shortage in the U.S.

Why depression after traumatic brain injury is distinct

Biogen nominates mother of director’s child to replace him on board

entertainment

hotspot

leisure time

focus